Aldeyra's roller coaster month ends with 'positive' phase 2 chronic cough readout

June has been something of a roller coaster month for Aldeyra Therapeutics. The immune-focused biotech has dived from the highs of a phase 3 win down to an FDA rejection and has now leveled out on some positive, if uninspiring, midstage data.